Analysis of B-Raf and MPC1 mutations & their correlation with specific DNA methylation patterns using de-identified, FFPE clinically annotated colorectal-specific tumor samples.

Information

  • Research Project
  • 9995760
  • ApplicationId
    9995760
  • Core Project Number
    R01CA116468
  • Full Project Number
    7R01CA116468-15
  • Serial Number
    116468
  • FOA Number
    PA-18-590
  • Sub Project Id
  • Project Start Date
    9/1/2019 - 4 years ago
  • Project End Date
    6/30/2021 - 3 years ago
  • Program Officer Name
    HILDESHEIM, JEFFREY
  • Budget Start Date
    9/1/2019 - 4 years ago
  • Budget End Date
    6/30/2021 - 3 years ago
  • Fiscal Year
    2019
  • Support Year
    15
  • Suffix
  • Award Notice Date
    9/23/2019 - 4 years ago
Organizations

Analysis of B-Raf and MPC1 mutations & their correlation with specific DNA methylation patterns using de-identified, FFPE clinically annotated colorectal-specific tumor samples.

Our long-term goal is to facilitate the development of new prevention and therapeutic measures for colon cancer formation by understanding the earliest cellular perturbations that follow APC mutation. In the previous funding periods, we revealed an innovative model wherein APC promotes enterocyte differentiation by controlling retinoic acid biosynthesis. These findings now demonstrate that the functions of APC are not limited to its well-established role in regulating canonical WNT signaling. Mechanistically, we identified the transcriptional co-repressor, C-terminal binding protein (CtBP), as a novel, APC-regulated protein that suppresses retinol dehydrogenases and intestinal cell differentiation in concert with dysregulated LEF-1. Early adenomas taken from FAP patients showed elevated levels of CtBP and LEF1 in comparison to adjacent, uninvolved tissues. Surprisingly, however, these same sections showed little evidence of nuclear ?-catenin indicating that loss of retinoic acid and cell differentiation precedes nuclear accumulation of ?-catenin. We further demonstrated that activation of KRAS promoted the accumulation of nuclear ?-catenin and subsequent intestinal cell proliferation. We also described and uncovered an unexpected connection between APC and a novel DNA demethylase system. This DNA demethylase is upregulated upon loss of APC and retinoic acid and maintains intestinal cells in progenitor-like state. This failed differentiation precedes K-RAS induced proliferation via ?-catenin. It is currently unclear where signals for activating KRAS, and therefore, ?-catenin originate in the context of APC loss. Interestingly, adult zebrafish made deficient in retinoic acid demonstrate both differentiation defects and a profound proliferation response that is coincident with activation of inflammatory stromal cells. Our preliminary findings indicate that adult zebrafish engineered to lack immune cells show intestinal differentiation defects, but no proliferative response when made deficient in retinoic acid. We will now expand our studies to examine whether retinoic acid plays roles in both epithelial cells and in intestinal stromal cells and whether interactions between these two cell populations account for both initiation and progression of colon adenomas. We hypothesize that APC controls the production of retinoic acid. Control of retinoic acid production in intestinal epithelial cells regulates cell potential for differentiation by remodeling the epigenetic landscape. In parallel, retinoic acid acts to suppress intestinal inflammatory responses that are need to stimulate epithelial cell proliferation. This project will expand our understanding of how APC and retinoic acid contribute to intestinal development and differentiation. This understanding could support a testable clinical hypothesis aimed at pharmacological re-activation of retinoid signaling in preventing and treating human colon cancers.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    7
  • Direct Cost Amount
    194000
  • Indirect Cost Amount
    87300
  • Total Cost
    281300
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
    NCI:281300\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MONC
  • Study Section Name
    Molecular Oncogenesis Study Section
  • Organization Name
    IHC HEALTH SERVICES, INC.
  • Organization Department
  • Organization DUNS
    072955503
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    841111633
  • Organization District
    UNITED STATES